Acute Spinal Cord Injury – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Acute Spinal Cord Injury Market Outlook

Thelansis’s “Acute Spinal Cord Injury Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Spinal Cord Injury treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Spinal Cord Injury Overview

An acute spinal cord injury (SCI) is a traumatic event that disrupts normal sensory, motor, or autonomic function, ultimately impacting a patient's physical, psychological, and social well-being. It comprises two phases: the primary and secondary phases. The primary phase involves the initial mechanical damage to the spinal cord, typically caused by spine deformation, direct compression, and neural element or blood vessel damage due to fractured or displaced bone fragments or disc material. The primary injury triggers the secondary phase and encompasses a series of biochemical and cellular processes, including electrolyte imbalances, the generation of free radicals, vascular ischemia, edema, posttraumatic inflammatory reactions, apoptosis, and other cellular responses.

Healthcare providers categorize SCIs into two types based on symptoms:

• Complete injury: Characterized by a lack of movement or sensation below the injury point.
• Incomplete injury: Where there is still some sensation or movement below the injury point.

Risk factors for SCI include:

• Individuals in the age range of 16-30 are at a higher risk of traumatic spinal injury.
• Statistics indicate that men are disproportionately more susceptible to spinal cord injuries.
• People over 65 are prone to spinal cord damage from falls.
• Pre-existing bone or joint disorders like osteoporosis or arthritis can increase susceptibility to spinal injuries.
• Engaging in risky behaviors such as diving into shallow waters or participating in sports without adequate protective gear can lead to spinal injuries.

In the United States, approximately 17,000 new cases of SCI occur each year, with an estimated 282,000 people living with SCI. The majority of SCI cases related to sports injuries involve males.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: